Literature DB >> 22133015

Dual task abilities as a possible preclinical marker of Alzheimer's disease in carriers of the E280A presenilin-1 mutation.

Sarah E MacPherson1, Mario A Parra, Sonia Moreno, Francisco Lopera, Sergio Della Sala.   

Abstract

Previous dual task studies have demonstrated that patients with sporadic Alzheimer's disease (AD) are impaired in their ability to perform two tasks simultaneously compared with healthy controls, despite being able to successfully perform the tasks alone relatively well. Yet, it remains unclear what the earliest clinical manifestation of this dual task coordination deficit is. This study examined dual task abilities in individuals who are at risk of early-onset familial AD due to an E280A presenilin-1 mutation. Thirty-nine carriers of the gene mutation who did not meet the criteria for AD and 29 non-carrier healthy controls were asked to perform digit recall accompanied by a secondary tracking task. Individuals who were carriers of the genetic mutation demonstrated significantly higher dual task costs than healthy non-carriers. Dual task performance was found to be more sensitive to this very early stage of FAD than episodic memory measures. The findings support the notion that a deficit in the coordination mechanism of the central executive may be a pre-clinical marker for the early detection of AD due to the E280A presenilin-1 gene mutation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22133015     DOI: 10.1017/S1355617711001561

Source DB:  PubMed          Journal:  J Int Neuropsychol Soc        ISSN: 1355-6177            Impact factor:   2.892


  6 in total

1.  The neuropsychology of normal aging and preclinical Alzheimer's disease.

Authors:  Richard J Caselli; Dona E C Locke; Amylou C Dueck; David S Knopman; Bryan K Woodruff; Charlene Hoffman-Snyder; Rosa Rademakers; Adam S Fleisher; Eric M Reiman
Journal:  Alzheimers Dement       Date:  2013-03-26       Impact factor: 21.566

2.  Normative Data for a Tablet-Based Dual-Task Assessment in Healthy Older Adults.

Authors:  Maxime Lussier; Kathia Saillant; Tudor Vrinceanu; Carol Hudon; Louis Bherer
Journal:  Arch Clin Neuropsychol       Date:  2021-10-13       Impact factor: 2.813

Review 3.  Promising developments in neuropsychological approaches for the detection of preclinical Alzheimer's disease: a selective review.

Authors:  Dorene M Rentz; Mario A Parra Rodriguez; Rebecca Amariglio; Yaakov Stern; Reisa Sperling; Steven Ferris
Journal:  Alzheimers Res Ther       Date:  2013-11-21       Impact factor: 6.982

4.  Genetic risk for neurodegenerative disorders, and its overlap with cognitive ability and physical function.

Authors:  Saskia P Hagenaars; Ratko Radaković; Christopher Crockford; Chloe Fawns-Ritchie; Sarah E Harris; Catharine R Gale; Ian J Deary
Journal:  PLoS One       Date:  2018-06-01       Impact factor: 3.240

5.  Accelerated long-term forgetting in presymptomatic autosomal dominant Alzheimer's disease: a cross-sectional study.

Authors:  Philip S J Weston; Jennifer M Nicholas; Susie M D Henley; Yuying Liang; Kirsty Macpherson; Elizabeth Donnachie; Jonathan M Schott; Martin N Rossor; Sebastian J Crutch; Christopher R Butler; Adam Z Zeman; Nick C Fox
Journal:  Lancet Neurol       Date:  2018-02       Impact factor: 44.182

6.  Visuomotor integration deficits are common to familial and sporadic preclinical Alzheimer's disease.

Authors:  Kirsty Lu; Jennifer M Nicholas; Philip S J Weston; Julie C Stout; Alison M O'Regan; Sarah-Naomi James; Sarah M Buchanan; Christopher A Lane; Thomas D Parker; Sarah E Keuss; Ashvini Keshavan; Heidi Murray-Smith; David M Cash; Carole H Sudre; Ian B Malone; William Coath; Andrew Wong; Marcus Richards; Susie M D Henley; Nick C Fox; Jonathan M Schott; Sebastian J Crutch
Journal:  Brain Commun       Date:  2021-01-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.